A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]
A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]
A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]
A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]
A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]
A handful of industrial biotechnology companies have the strength and purpose to make it as a public company — others remain private, are acquired, or wind down. What makes companies able to succeed with public investors? What combination of product mix, experienced management, technologies that excel, capital at work, and effective vision make it possible […]
Why should DOE work on plastics circularity? For one, ~2-3% of total energy consumption in the US is used to manufacture plastics, resins, and synthetic rubber. Also, plastic production generates ~3.8% of global GHGs. Finally, plastic production uses ~6% of global oil production, representing a large opportunity for further energy and process efficiency improvements. These […]
A team of researchers partnered with Visolis to develop a hydrogenolysis catalyst that can operate at low-pressures (≤ 5 MPa) and demonstrate conversion of a fermentation-derived C6 intermediate to a high value chemical monomer. The rewards? Risk and cost reduction for bioproduct process commercialization. And, developing a stable and selective catalyst for biomass conversion R&D. […]
What are the best pathways to generating and upgrading biochemical intermediates. For example, wet waste to mixed volatile fatty acids in arrested methanogenesis. Or, sugars to butyric acid, or 2,3 butanediol. Tasks include mitigation of scalability roadblocks, measurement of finished fuel properties and quantification of blend limitations, demonstration of life-cycle GHG emissions, and more. What’s […]
How can a public biofoundry develop and demonstrate capabilities that enable commercially-relevant biomanufacturing of a wide range of bioproducts by both new and established industrial hosts? The ABF has operated as a BETO-supported project since 2016. In 2017 the ABF expanded to a $20M/year BETO-consortium. The goal? To enable biorefineries to achieve 50% reductions in […]
